Sarepta Therapeutics Inc.
215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000
https://www.sarepta.com
版塊: Healthcare
行業: Biotechnology
全職員工: 1,314
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Douglas S. Ingram Esq. | President, CEO & Director | 1.62M | 無 | 1963 |
| Mr. Ian Michael Estepan | Executive VP & CFO | 917.53k | 無 | 1976 |
| Dr. Louise R. Rodino-Klapac Ph.D. | Executive VP, Chief Scientific Officer and Head of Research & Development | 1.04M | 無 | 1978 |
| Mr. Ryan E. Brown J.D. | Executive VP, General Counsel & Corporate Secretary | 823.36k | 無 | 1978 |
| Mr. Bilal Arif | Executive VP & Chief Technical Operations Officer | 無 | 無 | 1972 |
| Ms. Francesca T. Nolan | Executive Director of Investor Relations and Corporate Communications | 無 | 無 | 無 |
| Ms. Alison Nasisi | Executive VP & Chief People Officer | 無 | 無 | 無 |
| Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer | 無 | 無 | 無 |
| Mr. Dallan Murray | Executive VP & Chief Customer Officer | 無 | 無 | 無 |
| Mr. Will Tilton | Senior VP, Head of Strategy & Chief of Staff | 無 | 無 | 無 |
描述
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 2024年4月1日 止，Sarepta Therapeutics Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：7；董事會：3；股東權利：3；現金賠償：10。
